Competition

Competition — Who Can Hurt Sonova, and Who It Can Beat

Figures converted from CHF at historical FX rates — see data/company.json.fx_rates. Peer figures converted from their reporting currency at approximate period-end rates (EUR≈1.17, DKK≈0.157, AUD≈0.655, JPY≈0.0067, CHF≈1.26 to the US dollar). Ratios, margins, multiples and percentages are unitless and unchanged.

Sonova is the clear number-one in global hearing care, and the evidence says its moat is real but narrowing. The company is the global leader across the full value chain — devices, audiological retail and implants — serving people in more than 100 countries [1], it holds leading positions in the US and Europe, and it explicitly frames its technology engine as the benchmark in AI-driven audiology [2]. That leadership is earned, not asserted: management states it "clearly outperformed the market" in FY2025/26 [3].

But two things blunt the story. First, profitability has compressed hard — the operating margin has fallen from roughly 24% in FY2020/21 to about 19% today — even as the company gains units. Second, the moat is strongest exactly where the market is slowest (premium, prescription, clinician-fitted devices) and weakest exactly where the market is fastest (low-end over-the-counter and new form factors), a segment Sonova is now retreating from by divesting its Sennheiser-branded Consumer Hearing business.

Sonova's own differentiation claim is concrete and, unusually, benchmarked against rivals: its Audéo Sphere hearing aid, built on a proprietary "DEEPSONIC" real-time AI chip, is said to make wearers two-to-three times more likely to understand every word compared with leading competitors [5]. That is the crux of the bull case for the moat — and the rest of this tab tests it.

Sonova's competitive position at a glance

Sources: FY2025/26 continuing-operations revenue and EBIT margin, Financial Review [6]; R and D held at 6.0% of sales, FY2024/25 results presentation [7]; retail footprint of roughly 3,700 points of sale, Investor and Analyst Day 2024 [8].

The arena: a consolidated device oligopoly plus a vertically integrated retail race

Hearing care is a slow-growth, structurally attractive market: Sonova pegs mid-term hearing-aid market growth at roughly 4-6% per year by value, driven by aging populations and low penetration [9], and reiterates that structural-growth thesis in its FY2025/26 strategy [10]. Two structural features define who can hurt Sonova:

1. Manufacturing is a tight oligopoly. A handful of players make almost all of the world's prescription hearing aids — Sonova (Phonak, Unitron, Hansaton), Demant (Oticon, Bernafon, Philips), plus privately held WS Audiology (Widex, Signia), GN Store Nord (ReSound) and Starkey. Sonova's filings almost never name these rivals directly, referring to "leading competitors" and "the largest competitor" instead [11]. That the incoming CEO, Eric Bernard, was hired straight from the top job at WS Audiology underlines how small and interconnected this club is [12].

2. Distribution is fragmenting and consolidating at once. The route to the consumer runs through audiologists, ENT clinics, big retail chains, government/VA channels and now direct-to-consumer. Sonova's own Germany data shows how fragmented the front end still is: its GEERS/AudioNova retail arm holds about 14% of hearing-instrument units, a few named chains hold single digits each, and roughly 59% sits with smaller chains and independents [13]. That fragmentation is exactly what makes vertical integration — owning the clinics that fit the devices — the central strategic race, and it is where Amplifon and Demant are most dangerous.

Why these five comparators

The right peer set follows the value chain, not a market-cap screen. Four are genuine hearing-industry rivals with direct product or customer overlap; a fifth is the credible large-cap entrant threatening the low end.

• Demant A/S (DEMANT) — the closest pure-play rival, and the only one that mirrors Sonova's entire model: hearing aids, hearing-care retail and diagnostics all in one group [14].
• Amplifon (AMP) — the world's largest hearing-care retailer, self-described as "global leader in the distribution of hearing solutions" [15], holding roughly 13% of a hearing-care retail market it sizes at more than $21 billion [16]. It is both a channel Sonova sells through and a retailer Sonova competes against via AudioNova.
• Cochlear (COH) — the global leader in implantable hearing, and the direct rival to Sonova's Advanced Bionics in cochlear implants; the "largest competitor" whose new sound-processor launch pressured Sonova's CI sales [17].
• EssilorLuxottica (EL) — the large-cap entrant. Its Nuance Audio hearing glasses, cleared as an OTC device and now stocked in 15,000 stores across twelve markets [18], target Sonova's mild-to-moderate customers with a new form factor. Hearing is still immaterial to EL — it is not even a reported segment, appearing only as a "new product category" [19] — so it is an entrant to watch, not yet a peer to benchmark on economics.
• Audientes (AUDNTS) — a Danish micro-cap carried as a directional signal of the value/OTC end (its self-fitting "Ven" device) [20], not a scale benchmark; it is tiny and going-concern-stressed (see coverage table).

Sony (6758) is deliberately excluded from the benchmark set: its CRE-series OTC earbuds are immaterial inside an approximately $84-billion consumer-electronics group whose audio line is headphones and speakers, with no hearing-aid disclosure [21]. It is named as an OTC threat, not a financial comparator.

Peer comparison

Scale metrics are latest reported fiscal year, converted to US dollars at approximate period-end rates: Sonova FY2025/26 continuing operations [22]; Demant FY2025 group revenue $3,602m and 17.2% EBIT margin before special items [23] [24]; Amplifon FY2025 revenue about $2.8bn, +1.7% at constant FX (reported EBIT margin shown; adjusted EBIT margin is ~11.7%) [25]; Cochlear FY2025 (June year-end) and EssilorLuxottica FY2025 (reported operating margin; adjusted is ~15.7%) — company filings, as reported. Growth basis: Sonova = Hearing Instruments local-currency growth; Demant/Amplifon = organic/constant-FX; Cochlear/EL = reported/constant-FX. Market caps for Cochlear and EssilorLuxottica from staged price snapshots; Demant, Amplifon and Audientes market caps are not present in the run's staged data (see coverage table). Enterprise value is not reliably staged for any peer. P/E computed from latest EPS where a reliable market cap exists.

The table makes the shape of the fight clear. Sonova is a mid-cap (about $15.6bn) sitting between a giant conglomerate that barely does hearing (EssilorLuxottica, $33.3bn revenue) and a set of focused rivals its own size or smaller. On margins, the device-makers cluster together — Sonova 18.7%, Demant 17.2%, Cochlear 17.3% — while the retailer's model runs structurally leaner (Amplifon 8.2% reported EBIT; even adjusted, ~11.7%). That margin gap is the whole reason vertical integration is a double-edged sword: owning retail broadens access but dilutes the device-maker's premium economics.

Reported operating/EBIT margins, latest fiscal year: Amplifon and EssilorLuxottica are reported (adjusted margins are higher, ~11.7% and ~15.7% respectively); Demant is EBIT before special items [26]; Sonova is FY2025/26 continuing operations [27]. Cochlear and EssilorLuxottica per company filings, as reported.

Full coverage of every named competitor

Market caps for Cochlear and EssilorLuxottica from staged price snapshots; Audientes cap of about $1.1m per its own filing [28]. Demant and Amplifon caps are genuinely absent from the run's staged data (Amplifon's staged snapshot mis-resolved to a US financial firm and was rejected). Enterprise value is not reliably staged for any peer. Private manufacturers carry no public market cap. No competitor is invented or silently omitted.

Where Sonova wins

1. Proprietary AI silicon — a real technology lead at the premium end. Sonova designed its own DEEPSONIC real-time neural chip, exclusive to the Audéo Sphere platform, rather than buying a general-purpose part [29]. The payoff is a benchmarked outcome — wearers two-to-three times more likely to understand every word versus leading competitors [30] — and it is sustained by an R and D budget held around 6.0% of sales [31]. This is the most durable piece of the moat because full-stack chip design is hard for a private rival to replicate quickly.

2. It converts the lead into share — most visibly in the US Veterans Affairs channel. After the Sphere/Infinio launch, wholesale sales grew 9.5% in local currencies and Sonova says it "significantly expanded its market share globally" [32]. Its custom Virto R product now holds roughly 60% of the US VA in-the-ear segment, lifting Sonova's overall VA share to a five-year high [33]. VA matters because it is the single most competitive US wholesale battleground, where Demant is strong.

3. A top-tier vertically integrated retail network. Sonova's Audiological Care arm is the world's second-largest hearing-care provider, a position it has held for years — some 3,900 stores and clinics in 20 markets with over 8,600 staff back in FY2021/22 [34], around 3,700 points of sale and 10,500 employees by 2024 [35]. Its 70 "World of Hearing" flagship stores across 16 countries generate roughly twice the sales of a standard location [36]. Only Amplifon and Demant own retail at comparable scale.

4. A unique linked ear-to-implant offering. Because Sonova owns both Phonak hearing aids and Advanced Bionics implants, it is the only manufacturer able to offer linked two-ear solutions that pair a hearing aid and a cochlear implant designed to work together [37]. Cochlear and MED-EL cannot match this without a hearing-aid business.

Where competitors are better

1. Demant matches Sonova's model — and out-shares it in VA. Demant is the one rival that runs the same three-legged model (devices + retail + diagnostics) [38], at comparable device margins (17.2%) [39]. Crucially, Demant reports an 18.9% unit share in the US VA channel [40] — evidence that Sonova's VA strength is contested, not owned. Demant frames the industry as "an extremely competitive market" of highly specialised players [41].

2. Amplifon owns more of the consumer than Sonova does. As a dedicated retailer, Amplifon operates over 10,100 locations across 26 countries [42] — nearly triple Sonova's own store count — and roughly 13% of the global hearing-care retail market [43]. As a brand-agnostic buyer of everyone's devices, Amplifon holds pricing leverage over the manufacturers, including Sonova's wholesale arm.

3. Cochlear is the clear leader where Advanced Bionics is No. 2/3. In implants, Sonova is the challenger: its own filing attributes an 11.1% local-currency CI sales decline partly to increased competitive pressure after "the largest competitor" (Cochlear) launched a new product, compounded by China volume-based procurement [44]. Cochlear's larger installed base and R and D scale (over 12% of sales) set the pace in this segment.

4. EssilorLuxottica can out-distribute a new form factor overnight. Sonova has nothing like EL's retail reach: Nuance Audio went from launch to 15,000 stores across twelve markets in a single year [45], explicitly pitched to "remove the stigma surrounding traditional hearing aids" [46]. If glasses-as-hearing-aids catch on with mild-loss consumers, EL's distribution is a weapon Sonova cannot answer in kind.

Threat assessment

Threat evidence, in order: OTC/form-factor — EssilorLuxottica's OTC-cleared Nuance Audio in 15,000 stores [47] and Sonova's March-2026 decision to divest Consumer Hearing [48]; Demant — full-model overlap [49] and 18.9% VA share [50]; Amplifon — 10,100+ locations [51]; implants and VBP [52].

The most important call: the substitution threat cuts hardest at the low end, and Sonova is choosing to leave that fight. It entered US OTC in 2023 with a self-fitting Sennheiser device, arguing OTC would expand rather than cannibalise the prescription market [53]; yet in March 2026 it decided to divest the entire Consumer Hearing business to refocus on core hearing care [54] [55]. That is a defensible bet that Sonova's economics live in premium, clinician-fitted care — but it hands the low end to Apple, Sony and EssilorLuxottica, and makes the moat's durability entirely dependent on the premium tier staying premium.

Margin compression is the scoreboard to watch

Derived from Sonova reported financials, FY2020/21 through FY2025/26 (fiscal years ending March); FY2025/26 is continuing operations [56].

Even as Sonova gains units, its operating margin has fallen roughly five points from its FY2020/21 peak. Some of that is post-pandemic normalisation and pre-launch ASP pressure, but the trend is the clearest single sign that competitive intensity — from Demant's rival platform, Amplifon's channel power and reimbursement squeezes — is real. The FY2025/26 uptick to 18.7% is the bull's early evidence that Sphere-driven share gains can re-expand margins; that is the number the moat thesis lives or dies on.

Moat watchpoints

An investor deciding whether Sonova's position is strengthening or eroding should track these measurable signals:

1. US VA and overall US wholesale share vs Demant. Sonova's VA share is at a five-year high [57] while Demant sits at 18.9% units [58]. If Demant's VA number climbs after its next platform, the technology lead is narrowing.
2. Operating/core-EBIT margin trajectory. Watch whether the FY2025/26 recovery toward the high-teens continues, or whether ASP pressure and retail mix keep it capped. Sonova's mid-term target is a 7-12% Core EBIT CAGR [59].
3. R and D intensity. Held at ~6.0% of sales [60]. A sustained drop would signal the chip lead is being milked, not extended; a rise signals defence of the moat.
4. OTC / form-factor adoption at the mild-loss end. Track Nuance Audio's store count and reorder rates and Apple's hearing-aid feature uptake. If these expand the prescription funnel (Sonova's thesis) versus cannibalise it will decide whether exiting Consumer Hearing was wise.
5. Retail points-of-sale growth vs Amplifon. Sonova is scaling stores at about $100-125m of bolt-on spend a year; if Amplifon's 10,100-location lead widens, Sonova's access to the consumer erodes regardless of device quality.
6. Progress toward the ~$7.4bn revenue ambition. Management's FY2030/31 target [61] is the yardstick for whether share gains are compounding or stalling.